Targeting Oncogenic KRAS in Pancreatic Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：569 / 569
页数：1
相关论文
共 50 条
  • [31] Targeting the undruggable oncogenic KRAS: the dawn of hope
    Asimgil, Hande
    Ertetik, Utku
    Cevik, Nedim Can
    Ekizce, Menar
    Dogruoez, Alper
    Goekalp, Muazzez
    Arik-Sever, Elif
    Istvanffy, Rouzanna
    Friess, Helmut
    Ceyhan, Guralp Onur
    Demir, Ihsan Ekin
    JCI INSIGHT, 2022, 7 (01)
  • [32] Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer
    Cox, Adrienne D.
    Goodwin, Craig M.
    Bryant, Kirsten L.
    Dagliyan, Irem
    George, Samuel D.
    Lucas, Kelly E.
    Gautam, Prson
    Wennerberg, Krister
    Der, Channing J.
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
    Singh, Harshabad
    Keller, Rachel B.
    Kapner, Kevin S.
    Dilly, Julien
    Raghavan, Srivatsan
    Yuan, Chen
    Cohen, Elizabeth F.
    Tolstorukov, Michael
    Andrews, Elizabeth
    Brais, Lauren K.
    da Silva, Annacarolina
    Perez, Kimberly
    Rubinson, Douglas A.
    Surana, Rishi
    Giannakis, Marios
    Ng, Kimmie
    Clancy, Thomas E.
    Yurgelun, Matthew B.
    Schlechter, Benjamin L.
    Clark, Jeffrey W.
    Shapiro, Geoffrey I.
    Rosenthal, Michael H.
    Hornick, Jason L.
    Nardi, Valentina
    Li, Yvonne Y.
    Gupta, Hersh
    Cherniack, Andrew D.
    Meyerson, Matthew
    Cleary, James M.
    Nowak, Jonathan A.
    Wolpin, Brian M.
    Aguirre, Andrew J.
    CLINICAL CANCER RESEARCH, 2023, 29 (22) : 4627 - 4643
  • [34] RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
    Kang, R.
    Hou, W.
    Zhang, Q.
    Chen, R.
    Lee, Y. J.
    Bartlett, D. L.
    Lotze, M. T.
    Tang, D.
    Zeh, H. J.
    CELL DEATH & DISEASE, 2014, 5 : e1480 - e1480
  • [35] Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
    Linehan, Anna
    O'Reilly, Mary
    McDermott, Ray
    O'Kane, Grainne M.
    FRONTIERS IN MEDICINE, 2024, 11
  • [36] Targeting lipid metabolism disrupts KRAS oncogenesis in pancreatic cancer
    Arora, Neha
    Liang, Hong
    Reed, Alex
    Chang, Jeffrey T.
    Cravatt, Benjamin F.
    Zhou, Yong
    CANCER RESEARCH, 2024, 84 (06)
  • [37] Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
    Hou, Pingping
    Kapoor, Avnish
    Zhang, Qiang
    Li, Jiexi
    Wu, Chang-Jiun
    Li, Jun
    Lan, Zhengdao
    Tang, Ming
    Ma, Xingdi
    Ackroyd, Jeffrey J.
    Kalluri, Raghu
    Zhang, Jianhua
    Jiang, Shan
    Spring, Denise J.
    Wang, Y. Alan
    DePinho, Ronald A.
    CANCER DISCOVERY, 2020, 10 (07) : 1058 - 1077
  • [38] Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer
    Humpton, Timothy J.
    Alagesan, Brinda
    DeNicola, Gina M.
    Lu, Dan
    Yordanov, Georgi N.
    Leonhardt, Carl S.
    Yao, Melissa A.
    Alagesan, Priya
    Zaatari, Maya N.
    Park, Youngkyu
    Skepper, Jeremy N.
    Macleod, Kay F.
    Perez-Mancera, Pedro A.
    Murphy, Michael P.
    Evan, Gerard I.
    Vousden, Karen H.
    Tuveson, David A.
    CANCER DISCOVERY, 2019, 9 (09) : 1268 - 1287
  • [39] Oncogenic KRAS regulates pancreatic cancer cell signaling via stromal reciprocation
    Tape, Christopher
    Ling, Stephanie
    Dimitriadi, Maria
    McMahon, Kelly
    Worboys, Jonathan
    Leong, Hui S.
    Norrie, Ida
    Miller, Crispin
    Poulogiannis, George
    Lauffenburger, Douglas
    Jorgensen, Claus
    CANCER RESEARCH, 2016, 76
  • [40] Targeting KRAS selectively induce metabolic reprogramming in pancreatic cancer
    Shiekh, Laiba
    Cheung, Matthew
    Zheng, Linyuhui
    Marlette, Erica
    Ezeh, Chiamaka J.
    Conde, Don-Gerard
    Nwosu, Zeribe C.
    CANCER RESEARCH, 2024, 84 (17)
12345